Faylenel personal page - To The Moon

Faylenel

Faylenel

No personal profile

10Follow

2Followers

0Topic

0Badge

2021-12-22

$American Technologies,(AVCT)$cmonnnnn to themoon

2021-08-02

Yessss

How Novavax Could Shake Up the COVID Vaccine Market

2021-06-15

Really??

Elon Musk Says He’s Putting Last Remaining House on the Market

2021-06-14

$Sundial Growers Inc.(SNDL)$Hurryyy and fly to the moon!

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3563373689719112,"uuid":"3563373689719112","gmtCreate":1600279666797,"gmtModify":1623638773157,"name":"Faylenel","pinyin":"faylenel","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":10,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9000623322,"gmtCreate":1640164125239,"gmtModify":1676533504384,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AVCT\">$American Technologies,(AVCT)$</a>cmonnnnn to themoon","listText":"<a href=\"https://ttm.financial/S/AVCT\">$American Technologies,(AVCT)$</a>cmonnnnn to themoon","text":"$American Technologies,(AVCT)$cmonnnnn to themoon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000623322","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805767865,"gmtCreate":1627908128657,"gmtModify":1703497617784,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"Yessss","listText":"Yessss","text":"Yessss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805767865","repostId":"2156416128","repostType":2,"repost":{"id":"2156416128","pubTimestamp":1627888620,"share":"https://ttm.financial/m/news/2156416128?lang=&edition=fundamental","pubTime":"2021-08-02 15:17","market":"us","language":"en","title":"How Novavax Could Shake Up the COVID Vaccine Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2156416128","media":"Motley Fool","summary":"The latecomer could still carve out a spot for itself among the big vaccine makers.","content":"<p><b>Moderna</b> (NASDAQ:MRNA), <b>Johnson &amp; Johnson</b> (NYSE:JNJ), and <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> (NYSE:PFE) and its partner <b>BioNTech</b> (NASDAQ:BNTX)&nbsp;share the U.S. COVID-19 vaccine market right now. However, a much smaller company could soon be in a position to launch its vaccine. In this <i>Motley Fool Live</i> video <b>recorded on July 21</b>, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> (NASDAQ:NVAX) could potentially shake up the COVID vaccine market.</p>\n<p><b>Olivia Zitkus:</b> Let's move over to another vaccine maker without a vaccine on the market yet. Let's talk about Novavax. The U.S. currently has three approved vaccines or authorized vaccines, it's got Pfizer-BioNTech's, Moderna's, and Johnson &amp; Johnson's single-dose vaccine.</p>\n<p>But another <a href=\"https://laohu8.com/S/AONE.U\">one</a> can soon be on the way, Novavax is expecting to file for Emergency Use Authorization in the third quarter. If they can succeed, how could Novavax shake up the COVID-19 vaccine market?</p>\n<p><b>Keith Speights:</b> I think there are two ways that Novavax could potentially shake things up to at least to some extent. <a href=\"https://laohu8.com/S/FBNC\">First</a> of all, I think if studies find that Novavax's COVID-19 vaccine is significantly more effective against the delta variant than the other vaccines, I think demand both in the U.S. and in other countries will explode for Novavax's vaccine if that happens. That's <a href=\"https://laohu8.com/S/AONE.U\">one</a> scenario.</p>\n<p>Another one would be even without knowing the efficacy against the delta variant. I think Novavax could be a really attractive booster dose going forward. Assuming we will have booster doses there, but let's say 2022 and beyond, I think Novavax has a real good shot, no pun intended, about being among the top booster doses.</p>\n<p>I think those are two scenarios that could really be favorable for the company. Now, I don't expect though that Novavax is going to have a significantly big impact on the dynamics in the U.S. vaccine market in the near term. Again, unless there's some data that comes out showing really superior efficacy against the delta variant. But assuming that doesn't happen, I don't think Novavax can shake up things all that much in the U.S. market over the near term.</p>\n<p>The Pfizer-BioNTech and Moderna vaccines have commanding market share, Johnson &amp; Johnson is starting to gain a little. These companies are also working, particularly the messenger RNA companies, Pfizer-BioNTech and Moderna they're working to develop variant-specific vaccines and they have a head start on that front, I think that just puts them in a really good spot.</p>\n<p>Still though, I think Novavax will be able to carve out market share, particularly in international markets. Obviously, Olivia, this all assumes that Novavax wins Emergency Use Authorization for its vaccine based on the results from its late-stage studies, I think that's really likely. I think most people are fully expecting Novavax to win EUA in the relatively near term.</p>\n<p><b>Zitkus:</b> Yet at Phase 3 trial, again like Pfizer, and Moderna, and Johnson &amp; Johnson way above the 50-60% goal that the CDC in the FDA had set for vaccines way back over a year ago. It showed 89.7% efficacy against the alpha variant and then 96.4% efficacy against non-alpha variants.</p>\n<p>I think the alpha variant, was the one that had started to spread. We'd heard about that more in the U.K. I think that's the one that they looked at. It'll be interesting to see the performance versus delta, and whether Novavax could emerge as the supplier of booster shots, maybe not in the <a href=\"https://laohu8.com/S/UBNK\">United</a> States, but elsewhere should be really interesting.</p>\n<p>Anything else on Novavax, Keith, or should we hop over to, let's chat some BioNTech. I love BioNTech. [laughs]</p>\n<p><b>Speights:</b> The only other thing I would say on Novavax is it's still relatively small, certainly compared to the other biotechs that have vaccines on the market. Certainly a stock to watch. If the company wins EUA in the next few months, I think the stock could take off again.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Novavax Could Shake Up the COVID Vaccine Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Novavax Could Shake Up the COVID Vaccine Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) share the U.S. COVID-19 vaccine market right now. However, a much smaller company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156416128","content_text":"Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) share the U.S. COVID-19 vaccine market right now. However, a much smaller company could soon be in a position to launch its vaccine. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how Novavax (NASDAQ:NVAX) could potentially shake up the COVID vaccine market.\nOlivia Zitkus: Let's move over to another vaccine maker without a vaccine on the market yet. Let's talk about Novavax. The U.S. currently has three approved vaccines or authorized vaccines, it's got Pfizer-BioNTech's, Moderna's, and Johnson & Johnson's single-dose vaccine.\nBut another one can soon be on the way, Novavax is expecting to file for Emergency Use Authorization in the third quarter. If they can succeed, how could Novavax shake up the COVID-19 vaccine market?\nKeith Speights: I think there are two ways that Novavax could potentially shake things up to at least to some extent. First of all, I think if studies find that Novavax's COVID-19 vaccine is significantly more effective against the delta variant than the other vaccines, I think demand both in the U.S. and in other countries will explode for Novavax's vaccine if that happens. That's one scenario.\nAnother one would be even without knowing the efficacy against the delta variant. I think Novavax could be a really attractive booster dose going forward. Assuming we will have booster doses there, but let's say 2022 and beyond, I think Novavax has a real good shot, no pun intended, about being among the top booster doses.\nI think those are two scenarios that could really be favorable for the company. Now, I don't expect though that Novavax is going to have a significantly big impact on the dynamics in the U.S. vaccine market in the near term. Again, unless there's some data that comes out showing really superior efficacy against the delta variant. But assuming that doesn't happen, I don't think Novavax can shake up things all that much in the U.S. market over the near term.\nThe Pfizer-BioNTech and Moderna vaccines have commanding market share, Johnson & Johnson is starting to gain a little. These companies are also working, particularly the messenger RNA companies, Pfizer-BioNTech and Moderna they're working to develop variant-specific vaccines and they have a head start on that front, I think that just puts them in a really good spot.\nStill though, I think Novavax will be able to carve out market share, particularly in international markets. Obviously, Olivia, this all assumes that Novavax wins Emergency Use Authorization for its vaccine based on the results from its late-stage studies, I think that's really likely. I think most people are fully expecting Novavax to win EUA in the relatively near term.\nZitkus: Yet at Phase 3 trial, again like Pfizer, and Moderna, and Johnson & Johnson way above the 50-60% goal that the CDC in the FDA had set for vaccines way back over a year ago. It showed 89.7% efficacy against the alpha variant and then 96.4% efficacy against non-alpha variants.\nI think the alpha variant, was the one that had started to spread. We'd heard about that more in the U.K. I think that's the one that they looked at. It'll be interesting to see the performance versus delta, and whether Novavax could emerge as the supplier of booster shots, maybe not in the United States, but elsewhere should be really interesting.\nAnything else on Novavax, Keith, or should we hop over to, let's chat some BioNTech. I love BioNTech. [laughs]\nSpeights: The only other thing I would say on Novavax is it's still relatively small, certainly compared to the other biotechs that have vaccines on the market. Certainly a stock to watch. If the company wins EUA in the next few months, I think the stock could take off again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184628710,"gmtCreate":1623713612130,"gmtModify":1704209147452,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"Really??","listText":"Really??","text":"Really??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184628710","repostId":"1177842249","repostType":2,"repost":{"id":"1177842249","pubTimestamp":1623711268,"share":"https://ttm.financial/m/news/1177842249?lang=&edition=fundamental","pubTime":"2021-06-15 06:54","market":"us","language":"en","title":"Elon Musk Says He’s Putting Last Remaining House on the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1177842249","media":"Bloomberg","summary":"Tesla CEO announced plans to sell off possessions last year\nProPublica reported last week on billion","content":"<ul>\n <li>Tesla CEO announced plans to sell off possessions last year</li>\n <li>ProPublica reported last week on billionaires’ tax returns</li>\n</ul>\n<p>Tesla Inc.’s Elon Musk&nbsp;tweeted&nbsp;that he’s decided to sell the last of the homes he owns a week after a report said he and other billionaires paid little or no income taxes for several years.</p>\n<p><img src=\"https://static.tigerbbs.com/7f08ae440e7801cd874f9d154c871980\" tg-width=\"835\" tg-height=\"346\"></p>\n<p>The electric-car maker’s chief executive officertweetedearlier this month that he only has one house in the San Francisco Bay area that is rented out for events, and that if he sold, it “would see less use, unless bought by a big family, which might happen some day.”</p>\n<p>Musk, 49, first announced plans more than a year ago to sell his homes and&nbsp;most of his possessions&nbsp;as a way to&nbsp;blunt criticism&nbsp;of his wealth. Within days, he put two of his California properties&nbsp;on the market.</p>\n<p>Last week, ProPublica reported that Musk,Amazon.com Inc.&nbsp;CEO Jeff Bezos and&nbsp;Berkshire Hathaway Inc.&nbsp;Chairman Warren Buffett have paid&nbsp;little income tax&nbsp;relative to their outsize wealth, citing a trove of Internal Revenue Service data on tax returns for thousands of the wealthiest Americans. Musk paid no federal income taxes in 2018 and less than $70,000 in 2015 and 2017, according to the report.</p>\n<p>An IRS official&nbsp;said&nbsp;last week that the disclosure of the data for billionaires including Bloomberg LP founder Michael Bloomberg, the founder and majority owner of Bloomberg LP, the parent company of Bloomberg News, has been referred to Federal Bureau of Investigation investigators.</p>\n<p>After the ProPublica report, Musk tweeted that he will keep paying income taxes in California in proportion with his time in the state, which he said will be significant. He&nbsp;moved to Texas&nbsp;last year and said he now rents a roughly $50,000 house in Boca Chica from Space Exploration Technologies Corp., which has a launch site in the area.</p>\n<p><img src=\"https://static.tigerbbs.com/dc5e62253e47e4df34d41ca3d9fcd473\" tg-width=\"836\" tg-height=\"527\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk Says He’s Putting Last Remaining House on the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk Says He’s Putting Last Remaining House on the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 06:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-14/elon-musk-says-he-s-putting-last-remaining-house-on-the-market?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla CEO announced plans to sell off possessions last year\nProPublica reported last week on billionaires’ tax returns\n\nTesla Inc.’s Elon Musk tweeted that he’s decided to sell the last of the homes ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-14/elon-musk-says-he-s-putting-last-remaining-house-on-the-market?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-14/elon-musk-says-he-s-putting-last-remaining-house-on-the-market?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177842249","content_text":"Tesla CEO announced plans to sell off possessions last year\nProPublica reported last week on billionaires’ tax returns\n\nTesla Inc.’s Elon Musk tweeted that he’s decided to sell the last of the homes he owns a week after a report said he and other billionaires paid little or no income taxes for several years.\n\nThe electric-car maker’s chief executive officertweetedearlier this month that he only has one house in the San Francisco Bay area that is rented out for events, and that if he sold, it “would see less use, unless bought by a big family, which might happen some day.”\nMusk, 49, first announced plans more than a year ago to sell his homes and most of his possessions as a way to blunt criticism of his wealth. Within days, he put two of his California properties on the market.\nLast week, ProPublica reported that Musk,Amazon.com Inc. CEO Jeff Bezos and Berkshire Hathaway Inc. Chairman Warren Buffett have paid little income tax relative to their outsize wealth, citing a trove of Internal Revenue Service data on tax returns for thousands of the wealthiest Americans. Musk paid no federal income taxes in 2018 and less than $70,000 in 2015 and 2017, according to the report.\nAn IRS official said last week that the disclosure of the data for billionaires including Bloomberg LP founder Michael Bloomberg, the founder and majority owner of Bloomberg LP, the parent company of Bloomberg News, has been referred to Federal Bureau of Investigation investigators.\nAfter the ProPublica report, Musk tweeted that he will keep paying income taxes in California in proportion with his time in the state, which he said will be significant. He moved to Texas last year and said he now rents a roughly $50,000 house in Boca Chica from Space Exploration Technologies Corp., which has a launch site in the area.","news_type":1},"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185954030,"gmtCreate":1623631433220,"gmtModify":1704207254870,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>Hurryyy and fly to the moon!","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>Hurryyy and fly to the moon!","text":"$Sundial Growers Inc.(SNDL)$Hurryyy and fly to the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/185954030","isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":185954030,"gmtCreate":1623631433220,"gmtModify":1704207254870,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>Hurryyy and fly to the moon!","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>Hurryyy and fly to the moon!","text":"$Sundial Growers Inc.(SNDL)$Hurryyy and fly to the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/185954030","isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184628710,"gmtCreate":1623713612130,"gmtModify":1704209147452,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"Really??","listText":"Really??","text":"Really??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184628710","repostId":"1177842249","repostType":2,"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000623322,"gmtCreate":1640164125239,"gmtModify":1676533504384,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AVCT\">$American Technologies,(AVCT)$</a>cmonnnnn to themoon","listText":"<a href=\"https://ttm.financial/S/AVCT\">$American Technologies,(AVCT)$</a>cmonnnnn to themoon","text":"$American Technologies,(AVCT)$cmonnnnn to themoon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000623322","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805767865,"gmtCreate":1627908128657,"gmtModify":1703497617784,"author":{"id":"3563373689719112","authorId":"3563373689719112","authorIdStr":"3563373689719112","name":"Faylenel","avatar":"https://static.tigerbbs.com/5e6adf38263e6107c876224411960511","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563373689719112"},"themes":[],"htmlText":"Yessss","listText":"Yessss","text":"Yessss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805767865","repostId":"2156416128","repostType":2,"repost":{"id":"2156416128","pubTimestamp":1627888620,"share":"https://ttm.financial/m/news/2156416128?lang=&edition=fundamental","pubTime":"2021-08-02 15:17","market":"us","language":"en","title":"How Novavax Could Shake Up the COVID Vaccine Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2156416128","media":"Motley Fool","summary":"The latecomer could still carve out a spot for itself among the big vaccine makers.","content":"<p><b>Moderna</b> (NASDAQ:MRNA), <b>Johnson &amp; Johnson</b> (NYSE:JNJ), and <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> (NYSE:PFE) and its partner <b>BioNTech</b> (NASDAQ:BNTX)&nbsp;share the U.S. COVID-19 vaccine market right now. However, a much smaller company could soon be in a position to launch its vaccine. In this <i>Motley Fool Live</i> video <b>recorded on July 21</b>, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> (NASDAQ:NVAX) could potentially shake up the COVID vaccine market.</p>\n<p><b>Olivia Zitkus:</b> Let's move over to another vaccine maker without a vaccine on the market yet. Let's talk about Novavax. The U.S. currently has three approved vaccines or authorized vaccines, it's got Pfizer-BioNTech's, Moderna's, and Johnson &amp; Johnson's single-dose vaccine.</p>\n<p>But another <a href=\"https://laohu8.com/S/AONE.U\">one</a> can soon be on the way, Novavax is expecting to file for Emergency Use Authorization in the third quarter. If they can succeed, how could Novavax shake up the COVID-19 vaccine market?</p>\n<p><b>Keith Speights:</b> I think there are two ways that Novavax could potentially shake things up to at least to some extent. <a href=\"https://laohu8.com/S/FBNC\">First</a> of all, I think if studies find that Novavax's COVID-19 vaccine is significantly more effective against the delta variant than the other vaccines, I think demand both in the U.S. and in other countries will explode for Novavax's vaccine if that happens. That's <a href=\"https://laohu8.com/S/AONE.U\">one</a> scenario.</p>\n<p>Another one would be even without knowing the efficacy against the delta variant. I think Novavax could be a really attractive booster dose going forward. Assuming we will have booster doses there, but let's say 2022 and beyond, I think Novavax has a real good shot, no pun intended, about being among the top booster doses.</p>\n<p>I think those are two scenarios that could really be favorable for the company. Now, I don't expect though that Novavax is going to have a significantly big impact on the dynamics in the U.S. vaccine market in the near term. Again, unless there's some data that comes out showing really superior efficacy against the delta variant. But assuming that doesn't happen, I don't think Novavax can shake up things all that much in the U.S. market over the near term.</p>\n<p>The Pfizer-BioNTech and Moderna vaccines have commanding market share, Johnson &amp; Johnson is starting to gain a little. These companies are also working, particularly the messenger RNA companies, Pfizer-BioNTech and Moderna they're working to develop variant-specific vaccines and they have a head start on that front, I think that just puts them in a really good spot.</p>\n<p>Still though, I think Novavax will be able to carve out market share, particularly in international markets. Obviously, Olivia, this all assumes that Novavax wins Emergency Use Authorization for its vaccine based on the results from its late-stage studies, I think that's really likely. I think most people are fully expecting Novavax to win EUA in the relatively near term.</p>\n<p><b>Zitkus:</b> Yet at Phase 3 trial, again like Pfizer, and Moderna, and Johnson &amp; Johnson way above the 50-60% goal that the CDC in the FDA had set for vaccines way back over a year ago. It showed 89.7% efficacy against the alpha variant and then 96.4% efficacy against non-alpha variants.</p>\n<p>I think the alpha variant, was the one that had started to spread. We'd heard about that more in the U.K. I think that's the one that they looked at. It'll be interesting to see the performance versus delta, and whether Novavax could emerge as the supplier of booster shots, maybe not in the <a href=\"https://laohu8.com/S/UBNK\">United</a> States, but elsewhere should be really interesting.</p>\n<p>Anything else on Novavax, Keith, or should we hop over to, let's chat some BioNTech. I love BioNTech. [laughs]</p>\n<p><b>Speights:</b> The only other thing I would say on Novavax is it's still relatively small, certainly compared to the other biotechs that have vaccines on the market. Certainly a stock to watch. If the company wins EUA in the next few months, I think the stock could take off again.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Novavax Could Shake Up the COVID Vaccine Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Novavax Could Shake Up the COVID Vaccine Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) share the U.S. COVID-19 vaccine market right now. However, a much smaller company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/01/how-novavax-could-shake-up-the-covid-vaccine-marke/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156416128","content_text":"Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ), and Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) share the U.S. COVID-19 vaccine market right now. However, a much smaller company could soon be in a position to launch its vaccine. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how Novavax (NASDAQ:NVAX) could potentially shake up the COVID vaccine market.\nOlivia Zitkus: Let's move over to another vaccine maker without a vaccine on the market yet. Let's talk about Novavax. The U.S. currently has three approved vaccines or authorized vaccines, it's got Pfizer-BioNTech's, Moderna's, and Johnson & Johnson's single-dose vaccine.\nBut another one can soon be on the way, Novavax is expecting to file for Emergency Use Authorization in the third quarter. If they can succeed, how could Novavax shake up the COVID-19 vaccine market?\nKeith Speights: I think there are two ways that Novavax could potentially shake things up to at least to some extent. First of all, I think if studies find that Novavax's COVID-19 vaccine is significantly more effective against the delta variant than the other vaccines, I think demand both in the U.S. and in other countries will explode for Novavax's vaccine if that happens. That's one scenario.\nAnother one would be even without knowing the efficacy against the delta variant. I think Novavax could be a really attractive booster dose going forward. Assuming we will have booster doses there, but let's say 2022 and beyond, I think Novavax has a real good shot, no pun intended, about being among the top booster doses.\nI think those are two scenarios that could really be favorable for the company. Now, I don't expect though that Novavax is going to have a significantly big impact on the dynamics in the U.S. vaccine market in the near term. Again, unless there's some data that comes out showing really superior efficacy against the delta variant. But assuming that doesn't happen, I don't think Novavax can shake up things all that much in the U.S. market over the near term.\nThe Pfizer-BioNTech and Moderna vaccines have commanding market share, Johnson & Johnson is starting to gain a little. These companies are also working, particularly the messenger RNA companies, Pfizer-BioNTech and Moderna they're working to develop variant-specific vaccines and they have a head start on that front, I think that just puts them in a really good spot.\nStill though, I think Novavax will be able to carve out market share, particularly in international markets. Obviously, Olivia, this all assumes that Novavax wins Emergency Use Authorization for its vaccine based on the results from its late-stage studies, I think that's really likely. I think most people are fully expecting Novavax to win EUA in the relatively near term.\nZitkus: Yet at Phase 3 trial, again like Pfizer, and Moderna, and Johnson & Johnson way above the 50-60% goal that the CDC in the FDA had set for vaccines way back over a year ago. It showed 89.7% efficacy against the alpha variant and then 96.4% efficacy against non-alpha variants.\nI think the alpha variant, was the one that had started to spread. We'd heard about that more in the U.K. I think that's the one that they looked at. It'll be interesting to see the performance versus delta, and whether Novavax could emerge as the supplier of booster shots, maybe not in the United States, but elsewhere should be really interesting.\nAnything else on Novavax, Keith, or should we hop over to, let's chat some BioNTech. I love BioNTech. [laughs]\nSpeights: The only other thing I would say on Novavax is it's still relatively small, certainly compared to the other biotechs that have vaccines on the market. Certainly a stock to watch. If the company wins EUA in the next few months, I think the stock could take off again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}